Reimbursement treatment options for the treatment of severe eosinophilic asthma are expanded. GSK Korea's Nucala and Handok Teva Cinqair will be listed on the payroll simultaneously next month. Eisai's JAK inhibitor Jyseleca will also have new insurance coverage standards, and Novartis' JAK1/JAK2 inhibitor Jakavi will have coverage standards for Graft-versus-host reaction or disease (GVHD) added. Recently, the Ministry of Health and Welfare announced the details of the standards and methods for applying such nursing care benefits. We will begin collecting opinions until the 29th for implementation on the 1st of next month.

Nucala and Cinqair are used in adult patients with severe eosinophilic asthma wh